Skip to main content

Rosetta Genomics Collaborates with Rabin Medical on Women's Health Biomarker Tests

NEW YORK (GenomeWeb News) – Rosetta Genomics will work with the Rabin Medical Center in Israel to develop microRNA-based tests for women’s health, the company said today.
The company plans to use microRNA biomarkers to develop “a wide range of diagnostic and prognostic tests” in oncology, gynecology, and obstetrics, the Rehovot, Israel-based company said.
"There is true unmet medical need for better diagnostics in women's health, and I am confident that the Rabin Medical Center's world-renowned researchers will assist us in bringing better diagnostics to patients worldwide,” Rosetta Genomics CEO Amir Avniel said in a statement.
The Rabin Medical Center, comprised of the Beilinson and Hasharon Hospitals, is headquartered near Tel Aviv, and many of its medical and research staff hold posts at the Tel Aviv University Sackler School of Medicine.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.